Health & Science
COVID-19 vaccine for young kids could be ready this month
Posted on · Pfizer and BioNTech are expected to file for emergency use authorization with the Food and Drug Administration as early as Tuesday.
Posted on · Pfizer and BioNTech are expected to file for emergency use authorization with the Food and Drug Administration as early as Tuesday.
Posted on · In a highly anticipated decision, the Food and Drug Administration authorized Pfizer's Paxlovid as the first antiviral pill to treat COVID-19 at home.
Posted on · Experts address perceived concerns surrounding J&J, Pfizer, and Moderna vaccines, and how to gather safely this time of year amid the Omicron surge.
Posted on · Experts discuss mental health, self-care and overall wellness, as many struggle with depression and anxiety – especially during the holidays and winter months.
Posted on · In the U.S., the Pfizer vaccine is the only option for children and teenagers.
Posted on · The FDA on Friday granted emergency use authorization for the Pfizer-BioNTech and Moderna booster shots. The boosters have already been available for people 65 and older and to high-risk adults.
Posted on · The Food and Drug Administration is expected to announce later this week that it is authorizing boosters for people 18 or older, even if they aren't at risk for severe disease.
Posted on · After some debate, a group of scientists advising the FDA concluded that the vaccine's benefits outweigh its risks for young children.
Posted on · Some vaccine providers were ready to begin administering the booster shot as early as Friday.
Posted on · A third shot of the vaccine can be given at least six months after the two-dose regimen, according to the authorization. A booster rollout could begin this week.
Posted on · The vaccine maker said Monday it plans to seek authorization for this age group soon in the U.S., Britain and Europe -- a key step toward beginning vaccinations for youngsters.
Posted on · Advisers to the Food and Drug Administration voted against approval of a booster of the Pfizer-BioNTech COVID-19 vaccine for people 16 years and older. They later supported boosters for older people.
Posted on · More than 11% of those who received their first dose haven’t gotten a second shot, and more than 1 million people are more than 90 days overdue.
Posted on · A third dose of the COVID-19 vaccine is readily available for immunocompromised individuals, while the general public waits to gain access next month.
Posted on · The approval replaces the emergency use authorizations granted last December and could make it easier for employers, the military and universities to mandate vaccination.